Effectiveness and Safety of Intravenous Valproate in Agitation: a Systematic Review

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2021 Nov 16

PMID 34783884

Citations 2

Authors

Miriam Olivola

Serena Civardi

Stefano Damiani

Nicolo Cipriani

Andrea Silva

Alberto Donadeo

Pierluigi Politi

Natascia Brondino

Affiliations

Soon will be listed here.

Abstract

Rationale: The use of intravenous valproate is not approved for clinical practice in psychiatry. Literature data pointed out for a potential usefulness of this route of administration for valproate, but there is no actual consensus.

Objectives: The aim of the present systematic review is to assess the effectiveness of intravenous valproate in agitation as well as general safety.

Methods: A systematic review of studies evaluating the use of intravenous valproate in agitation was conducted. Additionally, safety was evaluated in all randomized trials involving the use of intravenous valproate in all medical conditions (epilepsy, migraine and psychiatric conditions).

Results: For the systematic review on effectiveness in agitation, the search yielded 965 articles overall. After removing duplicates, 9411 articles were screened by title and abstract, and 39 of these were evaluated at a full-text level. Six studies were considered eligible for qualitative synthesis: one RCT and case report (n = 3), followed by cohort studies (n = 2). For the systematic review on safety, twenty-two RCTs were considered eligible for quantitative synthesis.

Conclusion: Intravenous valproate seems efficacious in reducing agitation in psychiatric patients; it generally appears safe compared to other neuroleptics or antiepileptics. However, the evidence is still not strong as it relies mainly on open-label studies or case series.

Citing Articles

Anxiolytic and sedative effects of sodium valproate with different experimental paradigms in male and female rats.

de Los Angeles Cintado M, De La Casa L, Gonzalez G Neuropsychopharmacol Rep. 2024; 44(4):737-748.

PMID: 39270067 PMC: 11609752. DOI: 10.1002/npr2.12483.

Treatment of Aggressive Behavior and Agitation in an 11-Year-Old Boy with Co-Occurring Autism and ADHD: A Case Report and Literature Review on the Use of Intravenous Valproate in Emergency Psychiatry.

Carta A, Cavassa V, Puci M, Averna R, Sotgiu G, Valeri G J Clin Med. 2024; 13(12).

PMID: 38930101 PMC: 11204411. DOI: 10.3390/jcm13123573.

References

Asadollahi S, Heidari K, Hatamabadi H, Vafaee R, Yunesian S, Azadbakht A . Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial. Int Clin Psychopharmacol. 2014; 30(3):142-50. DOI: 10.1097/YIC.0000000000000064. View

Bak M, Weltens I, Bervoets C, De Fruyt J, Samochowiec J, Fiorillo A . The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis. Eur Psychiatry. 2019; 57:78-100. DOI: 10.1016/j.eurpsy.2019.01.014. View

Bakhshayesh B, Seyed Saadat S, Rezania K, Hatamian H, Hossieninezhad M . A randomized open-label study of sodium valproate vs sumatriptan and metoclopramide for prolonged migraine headache. Am J Emerg Med. 2013; 31(3):540-4. DOI: 10.1016/j.ajem.2012.10.014. View

Battaglia C, Averna R, Labonia M, Riccioni A, Vicari S . Intravenous Valproic Acid Add-On Therapy in Acute Agitation Adolescents With Suspected Substance Abuse: A Report of Six Cases. Clin Neuropharmacol. 2018; 41(1):38-42. DOI: 10.1097/WNF.0000000000000265. View

Bowden C . Acute and maintenance treatment with mood stabilizers. Int J Neuropsychopharmacol. 2003; 6(3):269-75. DOI: 10.1017/S1461145703003535. View

Calabrese J, Markovitz P, Kimmel S, Wagner S . Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol. 1992; 12(1 Suppl):53S-56S. DOI: 10.1097/00004714-199202001-00008. View

Calabrese J, Rapport D, Kimmel S, Reece B, Woyshville M . Rapid cycling bipolar disorder and its treatment with valproate. Can J Psychiatry. 1993; 38(3 Suppl 2):S57-61. View

Chen W, Gao R, Su Y, Zhao J, Zhang Y, Wang L . Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study. Eur J Neurol. 2011; 18(12):1391-6. DOI: 10.1111/j.1468-1331.2011.03420.x. View

Duggal H, Jagadheesan K, Gupta S, Basu S, Akhtar S, Nizamie H . Intravenous valproate: a new perspective in the treatment of manic symptoms. Indian J Psychiatry. 2011; 44(2):173-6. PMC: 2954347. View

10.

Foroughipour M, Ghandehari K, Khazaei M, Ahmadi F, Shariatinezhad K, Ghandehari K . Randomized clinical trial of intravenous valproate (orifil) and dexamethasone in patients with migraine disorder. Iran J Med Sci. 2013; 38(2 Suppl):150-5. PMC: 3771216. View

11.

Friedman B, Garber L, Yoon A, Solorzano C, Wollowitz A, Esses D . Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014; 82(11):976-83. DOI: 10.1212/WNL.0000000000000223. View

12.

Gagnon D, Fontaine G, Smith K, Riker R, Miller 3rd R, Lerwick P . Valproate for agitation in critically ill patients: A retrospective study. J Crit Care. 2016; 37:119-125. DOI: 10.1016/j.jcrc.2016.09.006. View

13.

Ghaleiha A, Haghighi M, Sharifmehr M, Jahangard L, Ahmadpanah M, Bajoghli H . Oral loading of sodium valproate compared to intravenous loading and oral maintenance in acutely manic bipolar patients. Neuropsychobiology. 2014; 70(1):29-35. DOI: 10.1159/000363344. View

14.

Gilad R, Izkovitz N, Dabby R, Rapoport A, Sadeh M, Weller B . Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand. 2008; 118(5):296-300. DOI: 10.1111/j.1600-0404.2008.01097.x. View

15.

GRUNZE H, Erfurth A, Amann B, Giupponi G, Kammerer C, Walden J . Intravenous valproate loading in acutely manic and depressed bipolar I patients. J Clin Psychopharmacol. 1999; 19(4):303-9. DOI: 10.1097/00004714-199908000-00003. View

16.

Hilty D, Rodriguez G, Hales R . Intravenous valproate for rapid stabilization of agitation in neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci. 1998; 10(3):365-6. DOI: 10.1176/jnp.10.3.365. View

17.

Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J . Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2009; 35(4):990-8. PMC: 2846602. DOI: 10.1038/npp.2009.202. View

18.

Hollander E, Tracy K, Swann A, Coccaro E, McElroy S, Wozniak P . Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003; 28(6):1186-97. DOI: 10.1038/sj.npp.1300153. View

19.

Kapur J, Elm J, Chamberlain J, Barsan W, Cloyd J, Lowenstein D . Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019; 381(22):2103-2113. PMC: 7098487. DOI: 10.1056/NEJMoa1905795. View

20.

Karimi N, Tavakoli M, Yazdani Charati J, Shamsizade M . Single-dose intravenous sodium valproate (Depakine) versus dexamethasone for the treatment of acute migraine headache: a double-blind randomized clinical trial. Clin Exp Emerg Med. 2017; 4(3):138-145. PMC: 5635457. DOI: 10.15441/ceem.16.199. View